A dataset describing a suite of novel antibody reagents for the RAS signaling network
Schoenherr RM, Huang D, Voytovich UJ, Ivey RG, Kennedy JJ, Saul RG, Colantonio S, Roberts RR, Knotts JG, Kaczmarczyk JA, Perry C, Hewitt SM, Bocik W, Whiteley GR, Hiltke T, Boja ES, Rodriguez H, Whiteaker JR, Paulovich AG. A dataset describing a suite of novel antibody reagents for the RAS signaling network. Sci Data [Internet]. 2019;6(1):160. Available from: https://doi.org/10.1038/s41597-019-0166-7
- Organism: Homo sapiens
- Instrument: QTRAP 5500,QTRAP 6500
RAS proteins, peptide-based immuno-MRM, monoclonal antibodies
RAS genes are frequently mutated in cancer and have for decades eluded effective therapeutic attack. The National Cancer Institute’s RAS Initiative has a focus on understanding pathways and discovering therapies for RAS-driven cancers. Part of these efforts is the generation of novel reagents to enable the quantification of RAS network proteins. Here we present a dataset describing the development, validation (following consensus principles developed by the broader research community), and distribution of 104 monoclonal antibodies (mAbs) enabling detection of 27 phosphopeptides and 69 unmodified peptides from 20 proteins in the RAS network. The dataset characterizes the utility of the antibodies in a variety of applications, including Western blotting, immunoprecipitation, protein array, immunohistochemistry, and targeted mass spectrometry. All antibodies and characterization data are publicly available through the CPTAC Antibody Portal, Panorama Public Repository, and/or PRIDE databases. These reagents will aid researchers in discerning pathways and measuring expression changes in the RAS signaling network.
Created on 12/21/18, 3:30 PM